Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.